Major Depressive Disorder (MDD)

An authoritative clinical profile of Major Depressive Disorder covering CANMAT 2016 guidelines, monoaminergic neurobiology, active suicidal crisis emergency red flags, and antidepressant non-discontinuation safety boundaries.

Editorial review complete

Independent clinical validation is pending.

Validation pending

Quick Reference Facts

System AffinityGeneral
Diagnostic StandardClinical evaluation & serum biomarkers
Urgency Levelroutine
Evidence GradeConsensus-Guidance

Evidence Summary

Body SystemClinical Medicine
Typical PrevalenceClinical review pending
Typical Age RangeClinical review pending
Clinical Urgencyroutine
Primary Etiological Factors
  • Monoaminergic (serotonin, norepinephrine, dopamine) neurotransmitter deficits and neuroendocrine HPA-axis hyperreactivity [D0020-KEYNOTES, CIT-0051]
  • Genetic vulnerability combined with environmental stressors, trauma, or chronic medical illness
  • Organic neurological/endocrine conditions (hypothyroidism, B12 deficiency, stroke, Parkinson's disease)
Recommended Screenings
Diagnosed via DSM-5-TR or ICD-11 criteria (≥5 of 9 symptoms including depressed mood or anhedonia)

Disease Progression Timeline

Stage 1 of 6

Risk Factors & Triggers

Underlying clinical predispositions, familial autoimmune markers, genetic anomalies, or environmental catalysts that establish susceptibility.

Clinical Pearl: Early screening of relatives with similar patterns is highly recommended.

Clinical Overview

Major Depressive Disorder (MDD) is a mood disorder characterized by persistent depressed mood, anhedonia (loss of interest/pleasure), psychomotor changes, and cognitive impairment lasting ≥2 weeks [D0020-KEYNOTES, CIT-0051]. CANMAT 2016 categorizes mild, moderate, and severe episodes.

Clinical Definition

A psychiatric mood disorder involving persistent depressed mood or loss of interest alongside neurovegetative, cognitive, and psychomotor symptoms causing marked functional impairment.

Pathological Causes

  • Monoaminergic (serotonin, norepinephrine, dopamine) neurotransmitter deficits and neuroendocrine HPA-axis hyperreactivity [D0020-KEYNOTES, CIT-0051]
  • Genetic vulnerability combined with environmental stressors, trauma, or chronic medical illness
  • Organic neurological/endocrine conditions (hypothyroidism, B12 deficiency, stroke, Parkinson's disease)

Risk Factors

  • Family history of mood disorders or completed suicide
  • Female sex, chronic pain/medical illness, social isolation, and severe life events (bereavement, job loss)
  • Substance use disorders or heavy alcohol abuse

Clinical Symptom Presentation

  • Persistent sad, empty, or anxious mood, and marked anhedonia in previously enjoyed activities [D0020-KEYNOTES, CIT-0051]
  • Significant weight loss/gain, insomnia or hypersomnia, and psychomotor agitation or retardation
  • Fatigue, feelings of worthlessness/excessive guilt, impaired concentration, and recurrent suicidal thoughts

Diagnostic Evaluation

Investigation Protocol

Diagnosed via DSM-5-TR or ICD-11 criteria (≥5 of 9 symptoms including depressed mood or anhedonia), PHQ-9 psychometric rating scale, and laboratory screening (TSH, B12/folate, CBC) to exclude organic etiologies [CIT-0051].

Differential Diagnosis

Differentiate MDD from Bipolar Affective Disorder (hypomanic/manic history), Persistent Depressive Disorder (Dysthymia), Hypothyroidism, Adjustment Disorder with Depressed Mood, and Bereavement.

Differential Diagnosis Matrix

Differential Diagnosis Overview

Differentiate MDD from Bipolar Affective Disorder (hypomanic/manic history), Persistent Depressive Disorder (Dysthymia), Hypothyroidism, Adjustment Disorder with Depressed Mood, and Bereavement.

Treatment Approaches

Conventional Management

Management includes evidence-based psychotherapy (CBT, Interpersonal Therapy), first-line antidepressants (SSRIs - fluoxetine, escitalopram; SNRIs; bupropion), and electroconvulsive therapy (ECT) or rTMS for severe treatment-resistant or catatonic depression [CIT-0051].

Homeopathic Approach

Homeopathic remedies (such as Aurum Metallicum, Ignatia Amara, Natrum Muriaticum, Sepia, Pulsatilla) act as supportive constitutional therapy to address emotional grieving, despondency, and lethargy alongside professional psychiatric supervision.

Lifestyle & Diet Advice

Maintain regular sleep-wake schedules, engage in daily aerobic exercise (proven to stimulate BDNF), practice mindfulness, avoid alcohol/drugs, and stay connected with supportive family and friends.

Reference Citations & Evidence Sources

Clinical Guidelines & Consensus Statements
  • CIT-0051Lam R. W., McIntosh D., Wang J.. "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder." The Canadian Journal of Psychiatry (2016).DOI PubMed
Materia Medica & Keynotes
  • CIT-0004Hahnemann S.. "Materia Medica Pura." Adolph Arnold (1811).
  • CIT-0005Kent J. T.. "Lectures on Homoeopathic Materia Medica." Boericke & Tafel (1905).
  • CIT-0006Boericke W.. "Pocket Manual of Homoeopathic Materia Medica." Boericke & Runyon (1901).

AI & Generative Search Citation Block

Entity IDD0020
Entity Typedisease
Content Versionv1.1.0
Last Reviewed DateJul 31, 2026
Evidence LevelConsensus-Guidance
Suggested Academic/LLM Citation format (AMA Style)

Dr. Narayan Jethwani. "Major Depressive Disorder (MDD)." Homeo Healthcare Clinical Platform. Version 1.1.0. Reviewed: 2026-07-31T12:00:00Z. Available at: https://homeo.healthcare/knowledge/diseases/depression

No clinical connections registered for this topic.

Medical Safety Disclaimer

All content on the Homeo Healthcare platform is strictly for educational purposes and is not personal medical advice, diagnosis, or treatment. Homeopathic remedy considerations are provided for clinician review or require individualized consultation with a qualified physician. Never delay seeking professional medical advice or emergency medical care due to content you have read on this website.